Ocular Therapeutix Inc
NASDAQ:OCUL
Ocular Therapeutix Inc
Operating Expenses
Ocular Therapeutix Inc
Operating Expenses Peer Comparison
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Ocular Therapeutix Inc
NASDAQ:OCUL
|
Operating Expenses
-$145.9m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-24%
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Expenses
-$35.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-1%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Expenses
-$24.1B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-11%
|
|
Pfizer Inc
NYSE:PFE
|
Operating Expenses
-$28.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-2%
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Expenses
-$39.8B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-8%
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Expenses
-$17.5B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-4%
|
See Also
What is Ocular Therapeutix Inc's Operating Expenses?
Operating Expenses
-145.9m
USD
Based on the financial report for Mar 31, 2024, Ocular Therapeutix Inc's Operating Expenses amounts to -145.9m USD.
What is Ocular Therapeutix Inc's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-24%
Over the last year, the Operating Expenses growth was -12%. The average annual Operating Expenses growth rates for Ocular Therapeutix Inc have been -19% over the past three years , -17% over the past five years , and -24% over the past ten years .